Top Story

EPA with statins may reduce periprocedural MI in PCI

November 21, 2014

Patients receiving eicosapentaenoic acid with statins before PCI experienced reduced type IVa MI compared with those receiving statins only, recent findings concluded.

The researchers aimed to investigate whether eicosapentaenoic acid (EPA), an omega-3 fatty acid, affects rates of periprocedural MI in an elective PCI setting. The full cohort included 165 of 178 consecutive patients with stable angina pectoris. Eligible participants underwent successful de novo stenting in the native coronary artery and were assigned to one of two treatment groups: statins with 1,800 mg per day of EPA, or statin monotherapy.

In the Journals

CDC: Overall heart disease death rate fell, increased in certain subtypes

November 21, 2014
In a letter published in JAMA, researchers from the CDC reported that mortality rates for heart disease overall have declined, but increases were seen in certain…
thumbnail for video 3903437995001 Meeting News CoverageVideo

VIDEO: Satellite-based ECG system may improve outcomes for patients with STEMI

November 21, 2014
CHICAGO — Srihari S. Naidu, MD, director of the cardiac catheterization lab at Winthrow University Hospital in Mineola, New York, provides perspective on results…
Meeting News CoveragePerspective

CONTROL-HTN: Mechanical device improved BP in patients with resistant arterial hypertension

November 21, 2014
Patients with treatment-resistant arterial hypertension had significant reductions in office-measured and ambulatory BP following arteriovenous anastomosis with a…
David I. Feldman, BS Meeting News Coverage

Subclinical vascular disease linked to erectile dysfunction

November 21, 2014
CHICAGO — Men with subclinical vascular disease are more likely to develop erectile dysfunction than men with no evidence of subclinical vascular disease…
More News Headlines »
Experts Take: Dialogue on HTG

Experts’ Take: Dialogue on Hypertriglyceridemia

This activity is supported by an independent educational grant from Amarin Pharma Inc.

Lead by genetic studies, recent data describe a causal role of triglycerides (TG) in the formation of atherosclerosis…
More »
Meeting News Coverage Video
Healio AHA2014 Zile th

New data may yield a 'change in the paradigm' of HF therapy

November 18, 2014
CHICAGO — Further analyses of the PARADIGM-HF trial provide more information on the efficacy of an…
More »
Controversial Issues and Challenging Cases

Controversial Issues and Challenging Cases in the New Frontier of Obesity Online Activity

This activity is supported by an educational grant from Eisai Inc.

Obesity has become a world-wide issue of utmost importance as its incidence and prevalence are associated with dramatic…
More »